Hélène Moins-Teisserenc
0000-0003-1602-7534
Université de Paris
73 papers found
Refreshing results…
Letter to the editor with regard to the article entitled “Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping”
BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis
Serum IgG2 levels predict long-term protection following pneumococcal vaccination in systemic lupus erythematosus (SLE)
Human-derived α1-antitrypsin is still efficacious in heavily pretreated patients with steroid-resistant gastrointestinal graft-versus-host disease
Compartiments immuns malins, T bénins conventionnels et régulateurs chez 36 patients traités par mogamulizumab pour CTCL avancé
Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR 3 DL 2 marker
Efficacy and safety of brentuximab vedotin plus bendamustine in advanced‐stage primary cutaneous T‐cell lymphomas
Safety of CD34+ Hematopoietic Stem Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46 in HIV-1 Infected Patients with High-Risk Lymphoma
Occurrence of Extensive Cutaneous Human Papillomavirus Infection After Initiation of Tofacitinib Therapy
Reconstitution of HIV-1 reservoir following high-dose chemotherapy/autologous stem cell transplantation for lymphoma
Malignant, benign conventional and regulatory T immune compartments in 36 patients treated with mogamulizumab for advanced CTCL
Ré-évaluation de la classification sanguine du mycosis fongoïde et du syndrome de Sézary à l’aide du marqueur KIR3DL2/CD158k
Association of autoimmunity and long‐term complete remission in patients with Sézary syndrome treated with mogamulizumab
Revisiting blood classification in Mycosis Fungoides and Sézary syndrome with the KIR3DL2 marker
Homeostatic proliferation leads to telomere attrition and increased PD-1 expression after autologous hematopoietic SCT for systemic sclerosis
Impaired long-term immune protection following pneumococcal 13-valent/23-valent polysaccharide vaccine in systemic lupus erythematosus (SLE)
Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients
Des cellules de Sézary : clonales mais versatiles
Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study
Missing publications? Search for publications with a matching author name.